BioMarin, following sluggish sales, to offload hemophilia gene therapy

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three years of slow uptake for a medicine once viewed as a future blockbuster.

Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

February 5, 2026

Lilly to acquire Verve in $1B bet on gene editing for heart disease

Lilly soars again as fast-selling weight loss drugs top Wall Street projections

February 4, 2026

Source link

BioMarin, following sluggish sales, to offload hemophilia gene therapy

Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

Lilly soars again as fast-selling weight loss drugs top Wall Street projections

Optical system performs feature extraction with unprecedented low latency

Man Has Pig Kidney Removed After Living With It for a Record 9 Months

Man Has Pig Kidney Removed After Living With It for a Record 9 Months

Leave a Reply Cancel reply

RECOMMENDED NEWS

Amazon doubles Anthropic investment to $8B

Africa Collective scales up 2024 Davos presence to convene international and pan-African private and public sector leaders.

Top UN rights body extends mandates for Russia and Sudan

BAE Announces Breakthrough in Explosives Manufacturing Tech

POPULAR NEWS

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

When Will SHIB Reach $1? Here’s What ChatGPT Says

BioMarin, following sluggish sales, to offload hemophilia gene therapy

Related posts

Optical system performs feature extraction with unprecedented low latency

Man Has Pig Kidney Removed After Living With It for a Record 9 Months

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS